BICX — BioCorRx Inc. Company Overview

Executive Summary

BioCorRx Inc. (OTC: BICX) is an Anaheim, California-based holding company operating in the addiction-treatment and weight-management space through a small network of licensed clinic partners, alongside an early-stage pharmaceutical subsidiary developing a novel opioid-use-disorder therapy. The company is a micro-cap, thinly traded OTC name with a market capitalization of roughly $6 million as of late August 2026 and a share price around $0.22. Fiscal 2025 revenue grew dramatically in percentage terms (up over 10,000% year over year to approximately $797,000) off a very small base, while the company remains unprofitable, posting a net loss of about $3.4 million for the year. The most consequential asset in the story is not the current clinic-licensing business but a $11.0 million multi-year grant from the National Institute on Drug Abuse (NIDA), awarded in March 2024, funding development of BICX104, a long-acting injectable naltrexone formulation for opioid and methamphetamine use disorder.

Core Business Model

BioCorRx operates a dual-track model: (1) a clinic-licensing business in which independent providers pay to offer the company's branded, proprietary treatment programs — combining medication-assisted treatment protocols, cognitive-behavioral therapy content, and a peer-support mobile app — under a franchise-like arrangement, and (2) a clinical-stage pharmaceutical development effort run through its subsidiary BioCorRx Pharmaceuticals Inc., funded substantially by non-dilutive NIDA grant capital rather than commercial product sales. This combination gives the company modest, program-fee-based recurring revenue from its licensed provider network while it works toward a potentially higher-value pharmaceutical asset (BICX104) that could eventually be licensed, partnered, or sold.

Business Segments

The company's two principal lines are: (1) the Beat Addiction Recovery Program and UnCraveRx® Weight Loss Program, both licensed to independent healthcare providers, and (2) pharmaceutical R&D via BioCorRx Pharmaceuticals, centered on BICX104. As of March 31, 2026, approximately 12 providers were licensed to offer the Recovery Program and 8 offered the Weight Loss Program — a small, still-nascent network that underscores the company's early commercial stage.

Product Portfolio

• Beat Addiction Recovery Program: A medication-assisted treatment (MAT) program combining physician-prescribed medications, proprietary cognitive behavioral therapy modules, and a peer-support mobile application, targeting opioid and alcohol use disorders.
• UnCraveRx® Weight Loss Program: A medication-assisted weight-management offering paired with "concierge on-demand" nutritionists and behavioral-health specialists.
• BICX104: A biodegradable, long-acting subcutaneous naltrexone pellet in development for opioid use disorder and methamphetamine use disorder, funded primarily by an $11,029,977 NIDA grant awarded March 1, 2024 (structured across three years: approximately $4.1 million in Year 1, $3.6 million in Year 2, and $3.3 million in Year 3). Grant income recognized was approximately $2.4 million in 2025, up from $1.5 million in 2024.

Competitive Landscape

BioCorRx competes in a crowded and better-capitalized addiction-treatment landscape against large medication-assisted-treatment providers (e.g., BioXcel Therapeutics, Indivior, which markets the leading naltrexone implant/injectable Vivitrol), national outpatient/behavioral-health chains, and a growing field of digital/telehealth addiction-treatment startups (Bicycle Health, Ophelia, Workit Health) that offer lower-friction virtual care models. On the pharmaceutical side, BICX104 will need to differentiate against Alkermes' Vivitrol (extended-release injectable naltrexone), the current standard long-acting MAT option, on dosing convenience, durability, or cost once (if) it reaches commercialization. BioCorRx's competitive position today rests less on scale or brand than on the NIDA grant validating its science and providing runway to reach clinical proof-of-concept for BICX104.

Strategic Strengths & Risks

The principal strength is the non-dilutive NIDA grant, which both validates the BICX104 science externally and reduces near-term dependence on dilutive equity financing for that specific program. Strengths also include an already-approved medication pathway (naltrexone is an established, FDA-approved active ingredient, which may streamline BICX104's regulatory route relative to a novel molecule) and a capital-light licensing model for its existing clinic programs. Risks are substantial and typical of a nano-cap OTC company: extremely small scale (only 3 employees noted in third-party data, and a licensed-provider network of just ~20 total sites), continued net losses ($3.4 million in 2025) against thin revenue, reliance on grant milestones that could be delayed or discontinued, dependence on third-party compounding pharmacies for BICX104 manufacturing (subject to FDA facility inspection risk), a very small market capitalization (~$6 million) and low trading liquidity that make capital raising difficult and dilutive, and direct competition from an already-approved, well-established long-acting naltrexone product (Vivitrol) that BICX104 must differentiate against to gain adoption.

Financial Overview

Fiscal 2025 revenue was approximately $797,244, an increase the company characterizes as over 10,000% year over year off a de minimis prior-year base, while net loss was approximately $3.44 million (EPS of approximately -$0.14). Grant income from NIDA, a separate line from program revenue, was approximately $2.44 million in 2025 versus $1.47 million in 2024. As of March 27, 2026, the company had approximately 26.4 million shares outstanding. As of late August 2026, market capitalization was approximately $6.25 million with shares trading around $0.217, reflecting the extremely small scale and speculative nature of the equity.

Summary Conclusion

BioCorRx is a nano-cap OTC company whose modest clinic-licensing business generates limited revenue relative to its cost base, leaving the NIDA-funded BICX104 long-acting naltrexone program as the primary long-term value driver. The non-dilutive grant funding is a genuine positive, but the company's small scale, continued losses, thin liquidity, and the presence of an established competing product (Vivitrol) make this a highly speculative, binary-outcome name dependent on both grant-funded clinical progress and eventual commercial or licensing success for BICX104.